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Abstract
Introduction: Computerized tomography is frequently employed in the critically ill, often using intravenous
radiocontrast material. Many of these patients have clinical features that are considered risk factors for contrast
induced nephropathy, but are simultaneously at risk for renal injury from other factors related to their acute
illnesses. The attributable risk for renal dysfunction from radiocontrast exposure has not been well quantified in this
population.
Methods: A prospective matched cohort study was conducted of patients scanned with or without radiocontrast
enhancement while receiving intensive care in a Veterans Affairs Medical Center. Patients were matched for pre-
scan measured creatinine clearance, diabetes, mechanical ventilation, and vasopressor use. Measured clearance was
followed for three days after scanning. Evolution of nephropathy, as determined by change in measured clearance,
was compared within matched pairs.
Results: Fifty-three pairs of patients satisfied matching criteria. Unmatched characteristics were similar among the
pairs, including serum creatinine variability during the week preceding scanning (67 ± 85% among contrast
recipients, 63 ± 62% among others) and clinical risk factors for renal failure. In 29 pairs, pre-scan measured
clearances were less than 60 mL/minute/1.73 m2. Following scanning, measured clearance declined by at least 33%
in 14 contrast and 19 non-contrast patients (95% confidence interval for contrast associated difference in
nephropathy rates -27% to 9%), while a 50% reduction in clearance persisted three days after scanning in three
contrast and nine non-contrast patients (95% confidence interval for difference in rates -25% to 2%).
Conclusions: Among established intensive care unit patients declines in glomerular filtration following contrast-
enhanced scanning are common, but these changes are far more likely to be attributable to factors other than the
contrast exposure itself. The upper bound for the incidence of contrast induced renal injury lasting even three days
was 2% in the population studied.
Introduction
Computerized tomography (CT) is invaluable for the
management of critically ill patients. While the intrave-
nous administration of iodinated radiographic contrast
media (RCM) may be helpful or essential for adequate
imaging, the potential complication of contrast induced
nephropathy (CIN) is a significant concern. While it has
no universally accepted definition, CIN typically refers
to an at least modest decline in the glomerular filtration
rate (GFR) occurring in the first days following RCM
exposure. Its pathophysiology remains uncertain, with
proposed mechanisms including medullary hypoxia, free
radical generation, and direct tubular toxicity [1].
Depending upon the population studied, CIN incidence
has ranged from 1% to more than 30% [2-12]. Risk factors
include impaired renal function, diabetes, anemia, and
hypotension [13-17], all common among ICU patients.
Critically ill patients have therefore been presumed to be
at relatively high risk for CIN [18-22]. However, analyses
of CIN risk factors have focused predominantly on
patients undergoing cardiac catheterization and have gen-
erally not included unexposed comparator populations.
The applicability of these findings to critically ill patients
undergoing CT scanning is therefore unknown.
The presumption that critically ill patients are at high
risk for CIN has clinical consequences. Perhaps most
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importantly, it may influence how often physicians avoid
exposing their critically ill patients to RCM during CT
scanning even when it would provide better imaging.
Furthermore, when contrast enhancement is utilized a
variety of measures may be employed in an attempt to
avert CIN, occasionally with unwanted consequences of
their own. It is axiomatic that development of rational
strategies to prevent CIN, either by prophylaxis or
avoidance of RCM exposure altogether, requires accu-
rate estimates of CIN incidence in populations of
interest.
CIN is usually recognized by a rise in serum creatinine,
with many investigators using as a threshold a 44 μmol/L
(0.5 mg/dL) absolute increase or a 25% relative increase
from before exposure. Identification of CIN among ICU
patients using serum creatinine is problematic for several
reasons: volatility of filtration with dynamic clinical
states; rapidly changing volumes of distribution, from
both disease and therapy; and varying creatinine produc-
tion. These may in part explain disparate reports of CIN
incidence among ICU patients [6,23,24]. The measured
creatinine clearance (mCrCl), a routinely available test
used in trials of critically ill patients [25], intrinsically
compensates for these phenomena and may provide
better estimates of GFR in the ICU setting [26-28].
As the initial phase of a planned program to investigate
the possible utility of very early markers of CIN in the cri-
tically ill, we undertook a prospective study of ICU
patients requiring CT scanning to better quantify their
risk of developing the syndrome and, in particular, to
determine whether it could be identified reliably in indivi-
dual patients. We opted to perform serial measurements
of mCrCl, before and after scanning, to identify changes in
renal function with high accuracy. Because lability of renal
function may lead to over-diagnosis of CIN even among
less acutely ill patients [29-31], we used matched ICU
patients scanned without contrast enhancement as
comparators.
Materials and methods
Subjects were recruited from the medical and surgical
ICUs of the Miami Department of Veterans Affairs Medi-
cal Center from 12 October 2004 through 2 December
2006. The Human Studies Subcommittee of the Research
and Development Committee (the Institutional Review
Board of the medical center) approved the study, permit-
ting urine collections before informed consent, but with
consent required for sample analysis and inclusion in the
study.
CTs were considered evaluable if done while the
patient was in the ICU, a urine collection on that day
was completed before the scan and the patient was
expected to remain in the ICU with an indwelling urin-
ary catheter for the succeeding three days.
Urine samples for creatinine clearance
Urine was collected nightly from all ICU patients with
indwelling urinary catheters who were not receiving renal
replacement therapy, with a standing order to start collec-
tions at approximately 11:00 PM. Exact start times were
recorded on data sheets supplied for the study. Collections
were ended the next morning, with the exact completion
time also recorded. Urine collection intervals thus
included the time of routine serum creatinine sampling
for ICUs in our institution. Collected urine volumes were
measured with laboratory grade graduated cylinders.
For the few patients transferred out of the ICU within
three days of a study CT, urine collections were contin-
ued in the same fashion on the ward.
Data collection
Age, sex, ethnicity, height, weight and history of hyperten-
sion, diabetes, liver disease and congestive heart failure
were recorded. The last serum albumin and hemoglobin
measurements before scanning were documented, along
with highest and lowest serum creatinine values from the
preceding week. All clinical measurements of serum crea-
tinine and urea nitrogen, along with the times samples
were obtained, from 48 hours before to 72 hours after
scanning, were logged. Data on exposure to nephrotoxins
and drugs that block tubular creatinine secretion (cimeti-
dine and trimethoprim) and administration of agents pro-
posed as prophylaxis against CIN, including sodium
bicarbonate and N-acetylcysteine, were collected.
The body area scanned, along with the type and volume
of RCM, was noted. Urine output from the three hours
and calendar day before scanning, and net fluid balance
from the 12 hours and calendar day before scanning, were
recorded. Urine outputs and fluid balances from the scan
day and the succeeding three days were also recorded.
Hemodynamic data included lowest blood pressure during
the 24 hours before scanning, hours from last vasopressor
use to the time of the scan, and lowest blood pressures
and hours of vasopressor use from the three consecutive
24 hour periods following scanning.
Study outcomes
The principal endpoint, chosen to be very sensitive to even
modest effects of RCM exposure, was a 33% reduction in
mCrCl relative to day 0 on any of the three subsequent
days. mCrCl was calculated using linear interpolation of
serum creatinine measurements to estimate serum creati-
nine at the midpoint of urine collection periods and was
considered 0 mL/minute in the event of death.
Secondary endpoints included a 50% reduction in
mCrCl at any time, a 33% reduction in mCrCl at three
days after scanning and, most relevant clinically, a 50%
reduction in mCrCl persisting three days after scanning.
Deterioration according to the Acute Kidney Injury
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(AKI) Network classification of renal disease [32], for-
mulated after this investigation was initiated, was later
added as an endpoint. (AKI Network criteria for oliguria
were only considered satisfied if present when averaged
over full days, rather than the six or 12 hour periods
permitted by the Network guidelines, because of the
pre-existing data format.) Relative changes in Cockcroft-
Gault (CG) [33] and six variable Modified Diet in Renal
Disease (MDRD) [34] estimated GFR were also
determined.
Analysis
Patients who underwent a CT with RCM were paired with
a patient scanned without RCM if the following could be
matched: day 0 mCrCl, adjusted for body surface area,
within 10%; vasopressor dependency within four hours
preceding the scan; requirement for invasive ventilatory
support at the time of scanning; and history of diabetes
mellitus. Additional restrictions imposed by the computer-
ized matching algorithm included: scans were only eligible
if patients did not have other RCM exposures from seven
days before until three days after the scan; and patients
could contribute only one matched scan.
Differences in dichotomous variables between matched
RCM and non-RCM patients were evaluated using McNe-
mar’s test with the binomial distribution, with confidence
intervals (CIs) calculated using Newcombe’s modification
of the Wilson score interval [35]. The significance of dif-
ferences in continuous variables was evaluated using the
paired t test or Wilcoxon’s test, depending upon the distri-
bution of differences within pairs. Analyses were done
using NCSS 2004 (Kaysville, UT, USA) and PASW Statis-
tics 17.0 (SPSS, Chicago, IL, USA).
Results
Pre-scan data
Throughout the study period 727 CT scans, 173 using
RCM, were performed during 2,228 ICU admissions. Two
patients with otherwise evaluable scans declined to partici-
pate, leaving 185 patients with 299 evaluable scans. A total
of 73 patients received RCM for 79 evaluable scans, and
matches were found for 53 of these patients (Figure 1).
Matched and unmatched pre-scan profiles are provided in
Table 1. Among matching criteria, invasive ventilation was
employed for 22 (42%) pairs, and vasopressors within the
four hours preceding scanning in two (4%) pairs. Fifteen
(28%) pairs had diabetes mellitus. The measured creatinine
clearances were 66 ± 30 mL/minute/1.73 m2 (mean ± SD)
and 65 ± 29 mL/minute/1.73 m2 among the RCM and
non-RCM patients respectively.
Typical of Department of Veterans Affairs popula-
tions, 105 (99%) of the patients were men. RCM and
non-RCM patients were similar with respect to disor-
ders that have been associated with CIN, including liver
disease and congestive heart failure (current or New
York Heart Association class III or IV by history), pre-
sent in 30 (28%) and 14 (13%) patients respectively
(Table 2). Both groups had marked relative hypotension
within the 24 hours preceding scanning (mean arterial
pressure 26 ± 21 mm Hg below pre-illness baseline in
RCM patients and 28 ± 21 mm Hg in non-RCM
patients, P > 0.6), with 38 (36%) patients having mean
arterial pressures less than 60 mm Hg (P > 0.4 for dif-
ference between groups). Eight (15%) patients in each
group had been newly diagnosed with sepsis during the
48 hours preceding scanning. Fluid balances over the 12
hours preceding scanning were similar among patients
who received RCM and those who did not (1,132 ±
1,550 mL versus 1,296 ± 2,159 mL, P = 0.50) (Table 3).
The volume of RCM administered was 144 ± 17 mL,
with 31 patients receiving iopromide (610 mOsm/L) and
22 iodixanol (290 mOsm/L). Patients receiving RCM
were more likely to have scans of the abdomen/pelvis or
chest and less likely of the head (P < 0.02 for each). CT
angiography was performed during 22 scans.
Pairs were well matched with regard to pre-scan renal
function (Table 4). Estimated clearances, serum creati-
nine and urea nitrogen, and urine flows differed little
within pairs. Substantial but similar variability of serum
creatinine, expressed as percent increase from the
observed minimum, was seen in the week preceding
scanning in both groups (67 ± 85% among RCM patients,
63 ± 62% among non-RCM patients, P = 0.9) (Figure 2).
Serum creatinine was generally at or near its pre-scan
minimum at the time of scanning.
N-acetylcysteine was given to 31 (58%) RCM patients
and bicarbonate to 33 (62%), with 42 (79%) patients
receiving some form of putative prophylaxis. Average fluid
administration exceeded three liters on the day of scan-
ning among both contrast and non-contrast patients.
Serial measures of renal function
Clearance measurements were based on urine collections
times of 9.41 ± 1.94 hours. Accompanying serum creati-
nine measurements were made 1.3 (IQR 1.0 to 1.5) times
per study day. The principal outcome, a 33% decline in
mCrCl at any time during the three days following scan-
ning, occurred in 14 (26%) RCM patients and 19 (36%)
non-RCM patients (95% CI for RCM associated incidence
change -27% to 9%, P = 0.32) (Table 5, Figure 3). mCrCl at
three days after scanning was less than half the pre-scan
clearance in three (6%) RCM patients and nine (17%) non-
RCM patients (95% CI for difference -25% to 2%, P = 0.08)
(Figure 4). The average peak decline in mCrCl was 19 ±
29% among RCM patients and 26 ± 39% among non-
RCM patients (P = 0.23). N-acetylcysteine and bicarbonate
were not associated with superior renal outcome among
RCM patients (P = 1.0).
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Estimates of GFR not utilizing urine creatinine were
less sensitive than mCrCl. The peak relative increase in
serum creatinine within three days of scanning was 9 ±
19% among patients exposed to RCM and 16 ± 58%
among those not (P = 0.38). Peak decline in CG esti-
mated clearance was 6 ± 16% and 5 ± 17% (P = 0.26)
among RCM and non-RCM patients, respectively, com-
parable to the values obtained using the MDRD equa-
tion (7 ± 20% and 6 ± 24%, P = 0.33). CG estimates
identified ten patients (two who received RCM) and
MDRD estimates 11 patients (four who received RCM),
as having GFR fall by at least 33%.
2228 ICU admissions 
727 CT scans while in ICU 
(173 with contrast enhancement) 
2 patients declined to participate 
299 evaluable scans 
(pre-scan collection for clearance, 
catheter to remain for three days) 
220 without contrast 79 with contrast 





Figure 1 Screening, enrollment, and matching schema.
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Forty four (42%) patients satisfied AKI Network criteria
for acute kidney injury, 23 of whom received RCM and 21
who did not (95% CI for difference -14% to 21%, P = 0.67).
AKI Network level three injury, the most severe gradation,
occurred in five (9%) RCM and 11 (21%) non-RCM
patients (95% CI for difference -26% to 4%, P = 0.21).
In 29 matched pairs both patients had pre-scan mCrCl
less than 60 mL/minute/1.73 m2. Measured clearance after
scanning declined by at least 33% in 5 (17%) patients who
received RCM and 12 (41%) who did not (95% CI for dif-
ference -46% to 2%, P = 0.12). Thirty (52%) of these
patients, half of whom received RCM, qualified as having
acute kidney injury by AKI Network criteria. Level three
injury occurred in three (10%) RCM patients and nine
(31%) non-RCM patients (95% CI for difference -42% to
3%, P = 0.15).
The investigators judged that RCM enhancement would
have been desirable for four of the matched patients (8%)
scanned without it. Only one had a 33% decline in mea-
sured clearance by day three, while none of their four
matched contrast-exposed patients had renal injury. Two
patients received dialytic support within one week of scan-
ning, one of whom had received RCM. Two patients,
neither of whom received RCM, died within 72 hours of
scanning.
Matching proved impossible for six of eight patients
receiving vasopressors and RCM enhanced scanning.
None of these scans were followed by a 33% decline in
measured clearance.
Discussion
We studied critically ill patients receiving RCM for CT
scanning to determine their risk for CIN. Anticipating
lability in renal function from critical illness itself, we com-
pared these patients to a matched population scanned
without RCM. Significant declines in renal function were
frequent, but no more so among those scanned with RCM
than those scanned without. It is sobering to note that
absent a control population, the declines in renal function
observed in the RCM exposed patients would have
suggested a high CIN incidence.
To the contrary, CIN appears to have been, at most,
rare in the population we studied. Our data suggest that
among similar patients fewer than two per 100 should
suffer a 50% loss of filtration persisting even three days as
a consequence of RCM use. It is clear from our study



















2 66 ± 30 65 ± 29 97 ± 43 44 ± 33
Ventilated at time of scan 22 (42%) 22 (42%) 16 (62%) 98 (59%)
Pressor use in 4 hrs before CT 2 (4%) 2 (4%) 6 (23%) 19 (11%)
Diabetes 15 (28%) 15 (28%) 4 (15%) 62 (37%)
Age, years 70 ± 10 67 ± 13 61 ± 14 71 ± 12
Liver disease 17 (32%) 13 (25%) 5 (19%) 31 (19%)
CHF (current or Class III/IV) 5 (9%) 9 (17%) 3 (12%) 25 (15%)
SCr, μmol/L
Last value before scanning 92 ± 30 95 ± 41 64 ± 30 133 ± 84
Lowest in the preceding week 82 ± 28 85 ± 40 56 ± 21 108 ± 65
Highest in the preceding week 137 ± 80 134 ± 65 80 ± 31 171 ± 114
Last pre-scan BUN, mmol/L 7.1 ± 3.6 8.2 ± 4.6 4.6 ± 2.5 11.4 ± 7.1
Mean arterial pressure, mm Hg
Before acute illness (baseline) 93 ± 14 92 ± 14 95 ± 13 95 ± 15
Lowest 24 hrs pre-scan 67 ± 16 63 ± 16 70 ± 13 65 ± 15
FIO2 at time of scan, % 42 ± 23 39 ± 16 52 ± 30 46 ± 21
New sepsis before scan 8 (15%) 8 (15%) 8 (31%) 22 (13%)
Body area scanned
Head 19 (36%) 32 (60%) 4 (15%) 64 (38%)
Chest 35 (66%) 22 (42%) 16 (62%) 96 (58%)
Abdomen/pelvis 27 (51%) 10 (19%) 15 (58%) 44 (26%)
Contrast desirable 4 (8%) 17 (10%)
BUN, blood urea nitrogen; mClCr, measured creatinine clearance; CT, computerized tomography; CHF, congestive heart failure; FIO2, fraction of inspired oxygen;
SCr, serum creatinine.
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that CIN occurs infrequently compared to other renal
insults in the critically ill and loss of GFR after RCM
administration, when it occurs, cannot reliably be
ascribed to RCM exposure. The observed magnitude of
effect is not a consequence of study size. Even a much
larger study of similar patients could only be reasonably
anticipated to narrow the confidence bands for signifi-
cant adverse effects from RCM, but still within the upper
or lower bounds of the confidence intervals we found.
Our population had many characteristics considered
risk factors for CIN. Most had mCrCl less than 60 mL/
minute/1.73 m2 before scanning. Anemia, diabetes, con-
gestive heart failure and advanced age were common. A
widely cited tool [14] for predicting CIN incidence, devel-
oped from a population undergoing cardiac catheteriza-
tion, classified most of our patients as being at moderate
or high risk. The predicted incidence was 17%, even with-
out accounting for the relative hypotension and recent
























































































































aMatching criterion. CHF, congestive heart failure; CIN, contrast induced nephropathy; CT, computerized tomography.
Table 3 Matched patient characteristics before scanning.
Pairs Contrast Non-Contrast Difference Paired
P
Age, years 53 70 ± 10 67 ± 13 3 ± 15 0.1578
Mean arterial pressure, mm Hg
Before acute illness (baseline) 48 93 ± 14 92 ± 14 1 ± 20 0.7145
Lowest 24 hours pre-scan 53 67 ± 16 63 ± 16 3 ± 18 0.1935
Drop from baseline 48 26 ± 21 28 ± 21 -2 ± 28 0.6136
FIO2 at time of scan, % 53 42 ± 23 39 ± 16 3 ± 25 0.3068
12 hour pre-scan fluid balance, mL 48 1132 ± 1550 1296 ± 2159 -165 ± 2535 0.4984
Last pre-scan hemoglobin, g/L 53 95 ± 16 106 ± 22 -10 ± 31 0.0195
Serum albumin, g/L 53 25 ± 6 27 ± 7 -2 ± 9 0.1416
Days in ICU at time of scan 53 6.5 ± 9.7 5.6 ± 7.1 0.9 ± 11.7 0.7533
SOFA score 53 3.9 ± 2.4 4.2 ± 2.1 0.3 ± 3.1 0.5088
FIO2, fraction of inspired oxygen; SOFA, sequential organ failure assessment score.
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renal compromise prevalent among our patients. Indeed,
the true incidence of nephropathy within the contrast
exposed group was reasonably approximated by the
model, but our control group, with similar risks but no
contrast exposure, had comparable nephropathy rates.
The only randomized prospective trial of CIN prophy-
laxis for ICU patients, which compared theophylline with
N-acetylcysteine but employed neither a control arm nor
an unexposed arm [8], further underscores the need for
caution when ascribing cause. In that study, a 44 μmol/L
(0.5 mg/dL) rise in serum creatinine within 48 hours of
imaging was defined as CIN and implicitly attributed to
contrast exposure irrespective of comorbidities, and in
aggregate occurred after 6% of scans. We observed a
Table 4 Pre-scan renal function parameters.
Pairs Contrast Non-Contrast Difference Paired
P
mClCr, mL/minute
Scan day, normalized to BSAa 53 66 ± 30 65 ± 29 1 ± 5 0.2934
Scan day 53 78 ± 39 75 ± 34 3 ± 16 0.1768
Day before scan 24 78 ± 27 75 ± 28 4 ± 21 0.4102
Scan day calculated ClCr, mL/min
Cockcroft-Gault formula 53 86 ± 33 90 ± 46 -5 ± 48 0.8456
MDRD formula 53 75 ± 28 76 ± 34 -1 ± 31 0.8828
SCr, μmol/L
Last value before scanning 53 92 ± 30 95 ± 41 -4 ± 37 0.4860
Lowest in the preceding week 53 82 ± 28 85 ± 40 -3 ± 37 0.6899
Highest in the preceding week 53 137 ± 80 134 ± 65 3 ± 97 0.9753
SCr variability in pre-scan week, % 53 67 ± 85 63 ± 62 4 ± 106 0.9049
Last pre-scan BUN, mmol/L 53 7.1 ± 3.6 8.2 ± 4.6 -1.1 ± 5.4 0.2053
Urine vol in 3 hrs before scan, mL 53 311 ± 365 237 ± 168 74 ± 401 0.3503
aMatching criterion. BSA, body surface area; BUN, blood urea nitrogen; mClCr, measured creatinine clearance; MDRD, modification of diet in renal disease; SCr,
serum creatinine.
Figure 2 Variability and optimization of serum creatinine before scanning. Filled circles in the left panel represent the ratio of highest to
lowest serum creatinine during the week preceding scanning in individual matched patient pairs, and in the right panel the ratio of the last
serum creatinine measured before scanning to the lowest measured during the week preceding scanning. Filled triangles denote mean values
for the pairs. Serum creatinine declined toward its recent minimum with pre-scanning management similarly in both groups.
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similar overall incidence of nephropathy satisfying this
definition, 4%. However, all of the events in our study
happened to have occurred in patients scanned without
contrast (who thus had an 8% incidence), a group specifi-
cally studied because their risk profiles were comparable
to patients who were scanned with contrast.
Unlike other CIN investigations, we used mCrCl as the
principal assessment of GFR. Both the CG and MDRD
formulas presume normal creatinine generation and a
static GFR. Assessments of renal function derived solely
from serum creatinine suffer the same shortcomings.
Among critically ill patients with potentially abnormal
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Figure 3 Minimum mCrCl within the three days following scanning relative to pre-scan values. Filled circles represent individual matched
patient pairs, and the filled diamond mean values for contrast and non-contrast patients. Points above the diagonal line imply greater loss of
renal function in the patient who received contrast, and below the line greater loss in the patient who did not receive contrast.
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creatinine production [36,37] and labile filtration, mCrCl
may offer advantages over other commonly used esti-
mates of GFR [38].
However, measured creatinine clearance is not without
problems. It depends critically upon urine collections
being accurately timed and complete. By studying
patients with indwelling urinary catheters errors from
incomplete voiding were minimized. Accuracy of timing
was assured by recording when collections were started
and ended, rather than the common practice of specify-
ing the duration of collections in advance.
In addition to changes in GFR, creatinine based mea-
sures of renal function are sensitive to fluctuations in the
tubular secretion rate of creatinine. Interval institution or
cessation of drugs effecting secretion may falsely imply
changes in GFR. Use of these drugs, however, was rare,
and balanced between RCM and non-RCM patients.
Creatinine based measures may underestimate declines
in GFR if tubular secretion remains intact, particularly
when GFR is initially low. While other techniques for
measuring GFR, such as inulin or iothalamate clearance,
avoid this shortcoming, they cannot feasibly be employed
on a daily basis as this study required.
Properly obtained, mCrCl provides a more accurate pic-
ture of GFR in critically ill patients than the serum creati-
nine or CG or MDRD formulas. However, our key
finding remains unchanged irrespective of how GFR is
measured, and even what level of dysfunction defines
injury: the instability of renal function during critical ill-
ness overwhelms any signal from CIN, making it impossi-
ble to identify the syndrome accurately. Reinforcing this
point, the pre-scanning variability of serum creatinine
was of the same magnitude as that required to satisfy
CIN definitions of renal injury. Such lability effectively
precludes studying interventions to prevent CIN among
the critically ill without at least one of the following: a
biomarker more specific than GFR for CIN be identified
and used as a surrogate endpoint; or very large popula-
tions are studied, without attempt to attribute individual
events to contrast exposure. This caveat is also applicable
to investigations of other potential etiologies of renal
injury among the critically ill.
Our study has limitations. While scientifically prefer-
able, a randomized trial of contrast exposure is imprac-
ticable, as it would mandate either suboptimal imaging or
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Figure 4 mCrCl three days after scanning, relative to pre-scan values. Filled circles represent individual matched patient pairs, and the filled
diamond mean values for contrast and non-contrast patients. Points above the diagonal line imply greater loss of renal function in the patient
who received contrast, and below the line greater loss in the patient who did not receive contrast.
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principal of beneficence. We therefore employed a
matched pairs design. Matching might have inadvertently
paired RCM patients with unexposed patients at intrinsi-
cally higher risk for deterioration of GFR. Comparisons
of other unmatched patient characteristics do not suggest
this was the case. Furthermore, brain imaging, more
common among non-RCM patients, tests for pathologies
not generally associated with renal injury.
Because of the stringency of the matching algorithm
employed, matching proved impossible for most patients
receiving vasopressors. However, no unmatched RCM
enhanced scan of a patient who received vasopressors
was associated with even a 33% decline in measured
clearance. Somehow including these patients in the ana-
lysis could only have diminished further the upper
bounds for CIN incidence.
Perhaps more importantly, we could not study patients
with RCM exposures shortly after ICU admission, since
we required a pre-scan urine collection. These patients
may well differ from those scanned later in their ICU
stays. For example, there might be salutary effects of the
markedly positive pre-scan fluid balances among estab-
lished ICU patients. We therefore cannot exclude a possi-
bly substantial CIN risk for patients just arriving to the
ICU. We also could not study patients whose physicians
felt the risk of RCM exposure outweighed the benefits.
However, scanning with contrast was judged preferable
from an imaging standpoint for fewer than 10% of
patients scanned without contrast, including those who
could not be matched.
Previously, one has had to extrapolate from other popu-
lations when judging the CIN risk faced by ICU patients
and how best to manage it. Cardiac catheterization studies
have provided most of these data. The critically ill patients
we studied often had findings identified as CIN risk factors
in cardiology populations and received RCM volumes
comparable to those commonly administered during
coronary angiography. However, there are potentially
important differences between these populations: critically
ill patients received considerably more fluid than recom-
mended for cardiac catheterization CIN prophylaxis; expo-
sure to certain drugs effecting kidney function, including
diuretics and angiotensin pathway modulators, is likely
higher in the cardiac population; and catheterization
simultaneously poses a risk for cholesterol embolization.
Our study indeed suggests that extending CIN findings
from cardiac catheterization to CT scanning of the criti-
cally ill is unwarranted.
Conclusions
We performed a prospective case matched study to
determine the identifiability and frequency of CIN in the
critically ill. Our investigation places a very low upper
bound on CIN incidence in established ICU patients. The
attributable risk for clinically significant renal dysfunc-
tion lasting even three days is unlikely to exceed 2%,
which should inform planning for imaging studies.
Furthermore, in ICU patients attribution of declining
filtration to RCM exposure is unreliable because of the
background prevalence of deterioration in the absence of
exposure. Pending the validation of etiology specific bio-
markers, this limitation will likely apply not only to inves-
tigations of CIN but also of other potential causes of
acute renal injury in the critically ill as well.
Key messages
• Among established intensive care unit patients, the
risk for nephropathy lasting even three days as a
consequence of radiocontrast material use appears
to be small, less than 2%. This should be considered
when planning imaging studies for these patients.
• Individual cases of nephropathy occurring in criti-
cally ill patients after use of intravenous radiocontrast
material cannot be reliably attributed to the contrast
exposure.
• Interventional studies aimed at reducing cause-
specific renal injury in the critically ill will require
either biomarkers more specific than glomerular filtra-
tion rate or, alternatively, very large study populations.
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